Utilization of Palliative Care Consultations in Pediatric Oncology Phase I Clinical Trials

Overview

Journal Pediatr Blood Cancer

Specialties Hematology
Oncology
Pediatrics

Date 2019 Apr 24

PMID 31012246

Citations 3

Authors

Andrea Cuviello

Renee Boss

Nirali Shah

Haven Battles

Andrea Beri

Lori Wiener

Affiliations

Soon will be listed here.

Abstract

Pediatric phase I clinical oncology trials represent a unique cohort of patients who have not responded to standard therapies and remain highly vulnerable to treatment toxicity and/or disease burden. Incorporating a palliative care consultation into the care plan for those with relapsed/refractory cancer where chance of cure is limited is generally recommended. A retrospective chart review of pediatric phase I trials revealed that palliative care was consulted in <20% of patients, most often for symptom management. Efforts to increase the use of palliative services in this population may enhance quality of life for children and families enrolled in phase I studies.

Citing Articles

Symptom Documentation in Unstructured Palliative Care Notes of Children and Adolescents With Cancer.

Bernier Carney K, Wilkes J, Aderibigbe T, Stegenga K, Spraker-Perlman H, Linder L J Pain Symptom Manage. 2025; 69(4):409-419.e1.

PMID: 39826587 PMC: 11867843. DOI: 10.1016/j.jpainsymman.2025.01.004.

Alignment of Palliative Care Service Structure and Standards of Care for Adolescents and Young Adults with Cancer: An International Survey of Clinical Practice.

Sansom-Daly U, Evans H, Darlington A, Weaver M, Rosenberg A, Wiener L J Palliat Med. 2024; 27(12):1606-1617.

PMID: 39588678 PMC: 11698666. DOI: 10.1089/jpm.2024.0141.

Oncologist conceptualizations of pediatric palliative care: challenges and definitions.

Laronne A, Granek L, Wiener L, Feder-Bubis P, Golan H Support Care Cancer. 2021; 29(7):3981-3989.

PMID: 33392772 PMC: 8164966. DOI: 10.1007/s00520-020-05959-z.

Specialist paediatric palliative care for children and young people with cancer: A mixed-methods systematic review.

Taylor J, Booth A, Beresford B, Phillips B, Wright K, Fraser L Palliat Med. 2020; 34(6):731-775.

PMID: 32362212 PMC: 7243084. DOI: 10.1177/0269216320908490.

References

Lee D, Kochenderfer J, Stetler-Stevenson M, Cui Y, Delbrook C, Feldman S . T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2014; 385(9967):517-528. PMC: 7065359. DOI: 10.1016/S0140-6736(14)61403-3. View

Fouladi M, Park J, Stewart C, Gilbertson R, Schaiquevich P, Sun J . Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol. 2010; 28(22):3623-9. PMC: 2917318. DOI: 10.1200/JCO.2009.25.9119. View

Su J, Li X, Thompson P, Ou C, Ingle A, Russell H . Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clin Cancer Res. 2010; 17(3):589-97. PMC: 3064523. DOI: 10.1158/1078-0432.CCR-10-0738. View

Zhukovsky D, Herzog C, Kaur G, Palmer J, Bruera E . The impact of palliative care consultation on symptom assessment, communication needs, and palliative interventions in pediatric patients with cancer. J Palliat Med. 2009; 12(4):343-9. DOI: 10.1089/jpm.2008.0152. View

Levine D, Johnson L, Mandrell B, Yang J, West N, Hinds P . Does phase 1 trial enrollment preclude quality end-of-life care? Phase 1 trial enrollment and end-of-life care characteristics in children with cancer. Cancer. 2015; 121(9):1508-12. PMC: 4685940. DOI: 10.1002/cncr.29230. View

Horton T, Pati D, Plon S, Thompson P, Bomgaars L, Adamson P . A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res. 2007; 13(5):1516-22. DOI: 10.1158/1078-0432.CCR-06-2173. View

Weitman S, Langevin A, Berkow R, Thomas P, Hurwitz C, Kraft A . A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Clin Cancer Res. 1999; 5(9):2344-8. View

Tomlinson D, Bartels U, Gammon J, Hinds P, Volpe J, Bouffet E . Chemotherapy versus supportive care alone in pediatric palliative care for cancer: comparing the preferences of parents and health care professionals. CMAJ. 2011; 183(17):E1252-8. PMC: 3225448. DOI: 10.1503/cmaj.110392. View

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

10.

Kim A, Fox E, Warren K, Blaney S, Berg S, Adamson P . Characteristics and outcome of pediatric patients enrolled in phase I oncology trials. Oncologist. 2008; 13(6):679-89. PMC: 6953426. DOI: 10.1634/theoncologist.2008-0046. View

11.

Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

12.

Schmidt P, Otto M, Hechler T, Metzing S, Wolfe J, Zernikow B . Did increased availability of pediatric palliative care lead to improved palliative care outcomes in children with cancer?. J Palliat Med. 2013; 16(9):1034-9. DOI: 10.1089/jpm.2013.0014. View

13.

Mosse Y, Lim M, Voss S, Wilner K, Ruffner K, Laliberte J . Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013; 14(6):472-80. PMC: 3730818. DOI: 10.1016/S1470-2045(13)70095-0. View

14.

Smith M, Bernstein M, Bleyer W, Borsi J, Ho P, Lewis I . Conduct of phase I trials in children with cancer. J Clin Oncol. 1998; 16(3):966-78. DOI: 10.1200/JCO.1998.16.3.966. View

15.

Cherny N, Catane R . Attitudes of medical oncologists toward palliative care for patients with advanced and incurable cancer: report on a survery by the European Society of Medical Oncology Taskforce on Palliative and Supportive Care. Cancer. 2003; 98(11):2502-10. DOI: 10.1002/cncr.11815. View

16.

Hinds P, Wang J, Stern E, Macpherson C, Wharton C, Okorosobo R . Voices of children and adolescents on phase 1 or phase 2 cancer trials: A new trial endpoint?. Cancer. 2017; 123(19):3799-3806. PMC: 5610606. DOI: 10.1002/cncr.30782. View